Fig. 9: Therapeutics of 4T1 metastatic breast cancer.

a The representative images of antigen-specific T Cells by IFN-γ ELISpot (n = 3 experimental repeats). This experiment was repeated twice independently with similar results. b The quantification of antigen-specific T Cells by IFN-γ ELISpot (n = 3 experimental repeats). c Schematic illustration of tumor therapeutic profiles. Created with BioRender.com. d Primary tumor growth curves of 4T1 breast tumor-bearing mice treated with Vehicle, Vehicle+RT, GGd-NCPs+RT, aAGd-NWs+RT and aAGd-NWs+RT + αPD-L1 (n = 6 mice). Black and red arrows indicated drug/radiation and anti-PD-L1 antibody treatments, respectively. RT 5 Gy × 2 with fractions delivered 6 days apart. Anti-PD-L1 antibody (10.0 mg kg⁻¹ × 4 with fractions delivered 3 days apart) were administered via intraperitoneal injection 6 h after radiation therapy. e Primary excised 4T1 breast tumor weights (n = 6 mice). f Survival curves of 4T1 breast tumor-bearing mice. g Images of lungs fixed by Bouin’s solution and H&E sections of lungs, scale bar = 1 mm. h Quantification of metastatic lesions of the lungs (n = 6 mice). All data were shown as mean ± SD. Two-tailed Student’s t-test was used to calculate statistical differences between two groups, and one-way ANOVA analysis of variance was used for multiple groups. p values > 0.05 represented nonsignificance (N.S.) and p values < 0.05 represented statistically significant. Source data are provided as a Source Data file.